358 related articles for article (PubMed ID: 31691079)
41. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.
Lorenzen S; Hentrich M; Haberl C; Heinemann V; Schuster T; Seroneit T; Roethling N; Peschel C; Lordick F
Ann Oncol; 2007 Oct; 18(10):1673-9. PubMed ID: 17660494
[TBL] [Abstract][Full Text] [Related]
42. A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Lui A; Mulder K; Brezden-Masley C; Vickers M; Monzon J; Kennecke H; Goel R; Vos L; Ghosh S; Marginean H; Fields A; Maroun J; Spratlin J
Invest New Drugs; 2018 Aug; 36(4):674-682. PubMed ID: 29725881
[TBL] [Abstract][Full Text] [Related]
43. Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma.
Alici S; Buyukberber S; Alkis N; Benekli M; Ozkan M; Bilici A; Demirci U; Karaca H; Arpaci E; Gumus M; Altunbas M; Dane F; Turk HM;
Asian Pac J Cancer Prev; 2013; 14(1):423-7. PubMed ID: 23534766
[TBL] [Abstract][Full Text] [Related]
44. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.
Petrioli R; Marrelli D; Roviello F; D'Ignazio A; Torre P; Chirra M; Savelli V; Ambrosio MR; Francini G; Calomino N; Farsi M; Vernillo R; Francini E
Surg Oncol; 2020 Mar; 32():2-7. PubMed ID: 31670056
[TBL] [Abstract][Full Text] [Related]
45. Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma.
Pourghasemian M; Danandeh Mehr A; Molaei M; Habibzadeh A
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2337-2341. PubMed ID: 32856863
[TBL] [Abstract][Full Text] [Related]
46. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Dalla Chiesa M; Tomasello G; Buti S; Rovere RK; Brighenti M; Lazzarelli S; Donati G; Passalacqua R
Cancer Chemother Pharmacol; 2011 Jan; 67(1):41-8. PubMed ID: 20204366
[TBL] [Abstract][Full Text] [Related]
47. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
[TBL] [Abstract][Full Text] [Related]
48. [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?].
Adenis A; Samalin E; Mazard T; Portales F; Mourregot A; Ychou M
Bull Cancer; 2020 Jan; 107(1):54-60. PubMed ID: 31980145
[TBL] [Abstract][Full Text] [Related]
49. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.
Roth AD; Maibach R; Fazio N; Sessa C; Stupp R; Morant R; Herrmann R; Borner MM; Goldhirsch A; de Braud F
Ann Oncol; 2004 May; 15(5):759-64. PubMed ID: 15111343
[TBL] [Abstract][Full Text] [Related]
50. Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.
Cho YH; Kim SY; Hong Lee M; Yoo MW; Bang HY; Lee KY; Yoon SY
Gastric Cancer; 2012 Oct; 15(4):389-95. PubMed ID: 22237658
[TBL] [Abstract][Full Text] [Related]
51. A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.
Sebag-Montefiore D; Glynne-Jones R; Falk S; Meadows HM; Maughan T
Br J Cancer; 2005 Oct; 93(9):993-8. PubMed ID: 16249791
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.
Mauer AM; Kraut EH; Krauss SA; Ansari RH; Kasza K; Szeto L; Vokes EE
Ann Oncol; 2005 Aug; 16(8):1320-5. PubMed ID: 15919687
[TBL] [Abstract][Full Text] [Related]
53. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
Kim HS; Ryu MH; Zang DY; Ryoo BY; Yang DH; Cho JW; Lim MS; Kim MJ; Han B; Choi DR; Kim JH; Jung JY; Song H; Park CK; Kang YK
Gastric Cancer; 2016 Apr; 19(2):579-585. PubMed ID: 25997815
[TBL] [Abstract][Full Text] [Related]
54. Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.
Unek IT; Akman T; Oztop I; Unal OU; Salman T; Yilmaz U
Gastric Cancer; 2013 Jul; 16(3):428-34. PubMed ID: 23086560
[TBL] [Abstract][Full Text] [Related]
55. S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma: two parallel phase 1/2a studies.
Pfeiffer P; Qvortrup C; Krogh M; Schoennemann K; Vestermark LW; Jensen HA; Bjerregaard JK
Acta Oncol; 2017 Jan; 56(1):46-51. PubMed ID: 27911128
[TBL] [Abstract][Full Text] [Related]
56. [Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer].
Song Y; Li WW; Huang J
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):380-383. PubMed ID: 28535657
[No Abstract] [Full Text] [Related]
57. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
[TBL] [Abstract][Full Text] [Related]
58. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
59. Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer.
Wang X; Jin J; Li YX; Ren H; Fang H; Wang SL; Liu YP; Wang WH; Yu ZH; Song YW; Liu XF
World J Gastroenterol; 2014 Jan; 20(4):1067-73. PubMed ID: 24574780
[TBL] [Abstract][Full Text] [Related]
60. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]